Back to News
Market Impact: 0.2
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
Source: PR Newswire
Legal & LitigationHealthcare & Biotech
Schall, Brown & Schwartz LLP reminded investors of a securities class-action lawsuit against ARS Pharmaceuticals (NASDAQ: SPRY), alleging violations of Sections 10(b) and 20(a) of U.S. securities laws. The notice creates litigation and potential reputational risk for the biotech company, though the provided article excerpt contains no allegations detail, financial damages, deadlines, or company response.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment
SPRY-0.85
More News
- Looters hit 3,000 French businesses. Within hours, the haul was trending on Vinted under the riot’s date
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- J&J prostate cancer drug shows promising tumor responses in early trial
- Exclusive-Boeing supplier dispute has halted 777 freighter production for two months, sources say
- Meta shares are down 9% this week. Here's why Mike Khouw is buying now